Integrated ADC discovery strategy and antibody/protein cell line development expertise sharing

Topic 1：Accelerated ADC development via integrated antibody discovery platform

Speaker: Dr. Li Chen, Director of Biologics Discovery Dept., ProBio
Date: Mar. 02^th, 2023
Time:14:00-16:00 (BJT)

Speaker 1 Biography

Dr. Chen Li is the Director of Biologics Discovery Department of ProBio. After obtaining his doctorate in immunology from the University of Massachusetts School of medicine, he joined GenScript in 2015 and has been responsible for antibody drug discovery platform for the past seven years. He has more than 200 project experience in antibody drug discovery and Engineering innovation optimization, as well as three patents related to biopharmaceutical discovery.

Topic 1 Background

Antibody-drug conjugates, also known as ADC, is a combination of traditional chemotherapy and targeted biological molecule. Recent clinical development brings lots of attention to this particular therapy in oncology filed. In this webinar, we will briefly go over the history and trending of ADC construct, followed by detail discussion of the tools and strategies for antibody discovery, as well as pharmacology assessment of antibody-drug conjugate.

Topic 1 Abstract

Brief overview of history and current trending of antibody-drug conjugates.
Tools and strategies for naked antibody discovery for ADCs
Early-stage pharmacology evaluation of naked antibody for ADC application
Pharmacology assessment of ADC candidates

Topic 2：Reaching IND faster with accelerated & high-yielding cell line development

Speaker: Dr. Lijuan Xu, Senior Scientist of Process Development dept., ProBio
Date: Mar. 02^th, 2023
Time:14:00-16:00 (BJT)

Speaker 2 Biography

Dr. Lijuan Xu received her PhD Degree in Molecular Bacteriology and Infection from University of Copenhagen in 2022. After completing her PhD, she joined ProBio as a Senior Scientist of in Antibody Process Development Department. She is responsible for external technical communication on cell line development and CLD platform and capability improvement.

Topic 2 Background

Biopharmaceuticals such as antibodies and recombinant proteins represent rapidly expanding categories of drugs offering new therapeutic applications. Achieving maximum production of these molecules is dependent on many factors such as suitable host cells, expression vectors and culture conditions.

Here, we describe ProBio’s cell line development platform (ProCLD) supporting biopharmaceutical manufacturing with high productivity and purity. An optimized vector pGenHT1.0-UP containing two “TiterUp” elements is utilized for boosting protein production. For bispecific/multispecific antibodies, optimized vector strategies have been used to modulate the relative expression of different polypeptide chains, thereby alleviating the chain mispairing issues. Notably, the turnaround time from transfection to PCB generation has been shortened to 8 weeks with highest titer of 10 g/L.

In summary, we show that ProBio has established superior CLD platform guaranteeing the accelerated and high-yielding cell line development.

Topic 2 Abstract

Overview of ProBio’s cell line development (ProCLD)
Strategies we have established to overcome the challenges in cell line development
Shortened turnaround timeline to 8 weeks from plasmid to PCB
Fast-Growing Global Track Record